Tag: Phase 2
-
D3 Bio Secures FDA Clearance for Two INDs, Jumpstarting Phase 1 and Phase 2 Trials
FDA Clears Two INDs for D3 Bio, Launching Key Clinical Trials Shanghai-based D3 Bio, a clinical-stage biotechnology company focused on transformative oncology therapies, has announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications. The approvals enable a Phase 1 clinical trial for D3S-003 and a Phase 2…
-
D3 Bio Sees FDA IND Clearance for D3S‑003 and Elisrasib Combination Study
FDA Clearance Accelerates D3 Bio’s Oncology Programs The U.S. Food and Drug Administration (FDA) has granted clearance for two Investigational New Drug (IND) applications from D3 Bio, a global clinical‑stage biotechnology company focused on transforming cancer therapy. The approvals authorize a Phase 1 trial of D3S‑003 and a Phase 2 study examining Elisrasib (D3S‑001) in…
-
ImmunoForge to Accelerate Global Partnerships at JPM Healthcare Conference 2026
ImmunoForge to host strategic partnering meetings at JPMorgan Healthcare Conference 2026 ImmunoForge Co., Ltd., a Seoul-based biopharma company focused on advancing immuno-oncology therapies, announced plans to host a series of strategic partnering meetings during the 2026 JPMorgan Healthcare Conference in San Francisco. The company will actively engage with global pharmaceutical leaders to accelerate the U.S.…
-
Apnimed Reports Positive Phase 2 Results for Sulthiame in Obstructive Sleep Apnea Published in The Lancet
Groundbreaking Phase 2 Results for Sulthiame in Obstructive Sleep Apnea Apnimed has announced that its Phase 2 FLOW study evaluating sulthiame, an oral carbonic anhydrase inhibitor, met the primary endpoint across all dosing regimens and demonstrated statistically significant improvements across multiple efficacy measures for obstructive sleep apnea (OSA). The positive findings were published in The…
-
Apnimed Publishes Positive Phase 2 Flow Study Results for Sulthiame in Obstructive Sleep Apnea in The Lancet
Overview: Promising Phase 2 Results in The Lancet Apnimed has announced that positive Phase 2 results from the FLOW study evaluating sulthiame, an oral carbonic anhydrase inhibitor, have been published in The Lancet. The publication highlights that sulthiame met the primary endpoint across all tested doses and significantly improved a range of efficacy measures in…
-
Apnimed Announces Lancet Publication: Positive Phase 2 Results for Sulthiame in Obstructive Sleep Apnea
New Lancet Publication Highlights Positive Phase 2 Outcomes Apnimed has revealed breakthrough findings from its Phase 2 FLOW study, showing that sulthiame, an oral carbonic anhydrase inhibitor, met the primary endpoint across all doses tested in obstructive sleep apnea (OSA). The Lancet publication details how sulthiame not only achieved statistical significance on primary measures but…
-
Starship Super Heavy 11th Test Flight: Booster Crashes in Gulf of Mexico
SpaceX launches Starship Super Heavy on 11th test flight from Texas SpaceX undertook the eagerly anticipated 11th test flight of its Starship Super Heavy system, a crucial step in proving the feasibility of fully reusable rockets capable of ferrying humans and cargo to the Moon, Mars, and beyond. The launch, conducted from SpaceX’s Starbase facility…
-
Ireland launches Phase 2 of national Precision Oncology program to accelerate personalized cancer care
Ireland marks a new chapter in personalized cancer care with Phase 2 of Precision Oncology Ireland On 8 October, Ireland strengthened its commitment to precision medicine with the launch of Phase 2 of Precision Oncology Ireland (POI), the country’s leading and largest cancer research program. The initiative, announced by James Lawless TD, Minister for Further…
-
Ireland Expands Precision Oncology Ireland: Phase 2 Launch Poised to Transform Cancer Care
Ireland Launches Phase 2 of its National Precision Oncology Program On 8 October, Ireland marked a significant milestone in its fight against cancer with the launch of Phase 2 of Precision Oncology Ireland (POI). The event signals a bold expansion of the country’s leading cancer research program, built to advance personalised cancer research and patient…
-
Ireland’s Largest Cancer Research Programme Secures €28m for Phase 2 Expansion
Ireland’s Largest Cancer Research Programme Secures €28m for Phase 2 Expansion precision Oncology Ireland (POI), Ireland’s flagship cancer research initiative, has received €28 million in co-funding to launch Phase 2. The announcement, made by Minister for Further and Higher Education, Research, Innovation and Science James Lawless, marks a major milestone in the country’s commitment to…